These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
450 related items for PubMed ID: 9428817
1. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. Vincenti F, Kirkman R, Light S, Bumgardner G, Pescovitz M, Halloran P, Neylan J, Wilkinson A, Ekberg H, Gaston R, Backman L, Burdick J. N Engl J Med; 1998 Jan 15; 338(3):161-5. PubMed ID: 9428817 [Abstract] [Full Text] [Related]
2. Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody. Beniaminovitz A, Itescu S, Lietz K, Donovan M, Burke EM, Groff BD, Edwards N, Mancini DM. N Engl J Med; 2000 Mar 02; 342(9):613-9. PubMed ID: 10699160 [Abstract] [Full Text] [Related]
4. A single-dose daclizumab induction protocol in renal allograft recipients: a Chinese single center experience. Ji SM, Li LS, Cheng Z, Cheng DR, Sun QQ, Chen JS, Sha GZ, Liu ZH. Transplant Proc; 2007 Jun 02; 39(5):1396-401. PubMed ID: 17580147 [Abstract] [Full Text] [Related]
5. Two-dose daclizumab regimen in simultaneous kidney-pancreas transplant recipients: primary endpoint analysis of a multicenter, randomized study. Stratta RJ, Alloway RR, Lo A, Hodge E. Transplantation; 2003 Apr 27; 75(8):1260-6. PubMed ID: 12717213 [Abstract] [Full Text] [Related]
6. Interleukin-2 receptor blockade in cardiac transplantation: influence of HLA-DR locus incompatibility on treatment efficacy. Lietz K, John R, Beniaminovitz A, Burke EM, Suciu-Foca N, Mancini DM, Edwards NM, Itescu S. Transplantation; 2003 Mar 27; 75(6):781-7. PubMed ID: 12660501 [Abstract] [Full Text] [Related]
10. Daclizumab is associated with decreased rejection and improved patient survival in renal transplant recipients. Morris JA, Hanson JE, Steffen BJ, Chu AH, Chi-Burris KS, Gotz VP, Gordon RD. Clin Transplant; 2005 Jun 27; 19(3):340-5. PubMed ID: 15877795 [Abstract] [Full Text] [Related]
11. Induction therapy after cardiac transplantation: a comparison of anti-thymocyte globulin and daclizumab in the prevention of acute rejection. Carlsen J, Johansen M, Boesgaard S, Andersen CB, Arendrup H, Aldershvilet J, Mortensen SA. J Heart Lung Transplant; 2005 Mar 27; 24(3):296-302. PubMed ID: 15737756 [Abstract] [Full Text] [Related]
16. Experience with single-dose daclizumab in the prevention of acute rejection in heart transplantation. Cuppoletti A, Perez-Villa F, Vallejos I, Roig E. Transplant Proc; 2005 Nov 27; 37(9):4036-8. PubMed ID: 16386620 [Abstract] [Full Text] [Related]
19. Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status. Swiatecka-Urban A. Paediatr Drugs; 2003 Nov 27; 5(10):699-716. PubMed ID: 14510627 [Abstract] [Full Text] [Related]